Overview

Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Status:
NOT_YET_RECRUITING
Trial end date:
2028-03-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
Phase:
PHASE2
Details
Lead Sponsor:
Incyte Corporation